Tremelimumab
- Generic Name
- Tremelimumab
- Brand Names
- Imjudo, Tremelimumab AstraZeneca
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 745013-59-6
- Unique Ingredient Identifier
- QEN1X95CIX
- Background
Tremelimumab, formerly known as ticilimumab, is a fully human IgG2 monoclonal antibody directed against cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). CTLA-4 is a cell surface receptor expressed on activated T cells to act as a negative regulator for T cells. By binding to CTLA-4, tremelimumab enhances T cell-mediated killing of tumours and reduces tu...
- Indication
Tremelimumab is indicated for the treatment of adult patients with unresectable hepatocellular carcinoma in combination with durvalumab. It is also indicated in combination with durvalumab and platinum-based chemotherapy for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor...
- Associated Conditions
- Metastatic Non-Small Cell Lung Cancer, Unresectable Hepatocellular Carcinoma (HCC)
- Associated Therapies
- -
Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies
- Conditions
- Interventions
- First Posted Date
- 2018-05-29
- Last Posted Date
- 2024-06-07
- Lead Sponsor
- Anwaar Saeed
- Target Recruit Count
- 117
- Registration Number
- NCT03539822
- Locations
- 🇺🇸
University of Kansas Cancer Center, Westwood, Kansas, United States
🇺🇸UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors
- Conditions
- Interventions
- Drug: DurvalumabDrug: Cisplatin (dose level 4)Drug: Etoposide (dose level 1)Drug: Carboplatin (dose level 1)Drug: Carboplatin (dose level 2)Drug: Cisplatin (dose level 3)Drug: TremelimumabRadiation: External beam radiation (dose level 1)Drug: PemetrexedDrug: PaclitaxelDrug: Cisplatin (dose level 1)Radiation: External beam radiation (dose level 2)Drug: Etoposide (dose level 2)Drug: Cisplatin (dose level 2)Radiation: External beam radiation (standard)Radiation: External beam radiation (hyperfractionated)
- First Posted Date
- 2018-04-26
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 105
- Registration Number
- NCT03509012
- Locations
- 🇨🇳
Research Site, Taoyuan City, Taiwan
Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-03-29
- Last Posted Date
- 2022-09-08
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 70
- Registration Number
- NCT03482102
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Durvalumab (MEDI4736) and TREmelimumab in NEOadjuvant Bladder Cancer Patients (DUTRENEO)
- Conditions
- Interventions
- First Posted Date
- 2018-03-21
- Last Posted Date
- 2023-04-13
- Target Recruit Count
- 101
- Registration Number
- NCT03472274
- Locations
- 🇪🇸
Hospital Clinic, Barcelona, Spain
🇪🇸ICO L'Hospitalet, L'Hospitalet De Llobregat, Spain
🇪🇸ICO Badalona, Badalona, Spain
Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCC
- Conditions
- Interventions
- First Posted Date
- 2018-01-25
- Last Posted Date
- 2024-01-03
- Lead Sponsor
- Canadian Cancer Trials Group
- Target Recruit Count
- 129
- Registration Number
- NCT03410615
- Locations
- 🇧🇪
University Hospital of Gent, Gent, Belgium
🇧🇪AZ Sint Augustinus, Wilrijk, Belgium
🇨🇦Cross Cancer Institute, Edmonton, Alberta, Canada
Combination of Durvalumab and Tremelimumab as Maintenance Treatment in Patients With Non Squamous and Squamous (NSCLC)
- Conditions
- Interventions
Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder
- First Posted Date
- 2017-10-23
- Last Posted Date
- 2024-03-20
- Lead Sponsor
- Noah Hahn, M.D.
- Target Recruit Count
- 55
- Registration Number
- NCT03317158
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Stanford University, Stanford, California, United States
🇺🇸Rush University Medical Cneter, Chicago, Illinois, United States
Renal Adjuvant MultiPle Arm Randomised Trial
- First Posted Date
- 2017-09-20
- Last Posted Date
- 2020-09-07
- Lead Sponsor
- University College, London
- Target Recruit Count
- 1750
- Registration Number
- NCT03288532
- Locations
- 🇬🇧
The Christie, Manchester, United Kingdom
🇬🇧Royal Marsden Hospital, Sutton, United Kingdom
🇬🇧Aberdeen Royal Infirmary, Aberdeen, United Kingdom
Immunotherapy and SBRT for Metastatic Head and Neck Carcinomas
- Conditions
- Interventions
- First Posted Date
- 2017-09-14
- Last Posted Date
- 2024-06-28
- Target Recruit Count
- 45
- Registration Number
- NCT03283605
- Locations
- 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
🇨🇦London Regional Cancer Program of the Lawson Health Research Institute, London, Ontario, Canada
🇨🇦Centre Hospitalier de l'Université de Montréal, Montréal, Quebec, Canada
Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-09-11
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 16
- Registration Number
- NCT03277482
- Locations
- 🇺🇸
Martin King, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.